SCHEMBL3301392

SCHEMBL3301392

Cc1ccc2ccc(CNC3CCN(C(=O)c4ccc(Nc5nccc(Nc6ccc(F)c(C)c6)n5)cc4)CC3)cc2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 8/20 0.40
CDK1 P06493 4/20 0.40
PTK2 Q05397 1/20 0.39
DRD4 P21917 1/20 0.39
CCNE1 P24864 3/20 0.39
NTRK1 P04629 2/20 0.38
NTRK3 Q16288 1/20 0.38
NTRK2 Q16620 1/20 0.38
IGF1R P08069 1/20 0.38
IKBKB O14920 3/20 0.37
CHUK O15111 3/20 0.37
IKBKG Q9Y6K9 3/20 0.37
CCNA2 P20248 2/20 0.37
CCNK O75909 1/20 0.37
CDK7 P50613 1/20 0.37
CCNH P51946 1/20 0.37
MNAT1 P51948 1/20 0.37
CDK12 Q9NYV4 1/20 0.37
PDGFRB P09619 1/20 0.37
PDGFRA P16234 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3299998 0.95 PTK2 (0.40) CDK2CDK1PTK2DRD4CCNE1
SCHEMBL3301338 0.90 CDK2 (0.42) CDK2CDK1PTK2DRD4CCNE1
SCHEMBL3302821 0.87 TACR1 (0.40) CDK2CDK1PTK2CCNE1IKBKB
SCHEMBL3298135 0.86 IKBKB (0.39) CDK2CDK1PTK2DRD4CCNE1
SCHEMBL3301846 0.84 CDK2 (0.42) CDK2CDK1PTK2CCNE1IGF1R
SCHEMBL3299563 0.84 PTK2 (0.42) CDK2CDK1PTK2CCNE1NTRK1
SCHEMBL3301960 0.83 CDK1 (0.41) CDK2CDK1PTK2CCNE1IGF1R
SCHEMBL3299108 0.83 PTK2 (0.42) CDK2CDK1PTK2CCNE1IGF1R
SCHEMBL3302490 0.83 CDK2 (0.53) CDK2CDK1PTK2CCNE1NTRK1
SCHEMBL3302433 0.82 CDK2 (0.40) CDK2CDK1PTK2CCNE1IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS CHUK, IKBKB, IKBKE CDK2 8/4885CDK1 15/4885PTK2 622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.